The Science Behind Cirela
Our formulas are supported by two types of evidence: published research on key ingredients and testing performed on the finished Cirela formulas.
PDRN Pink Peptide Serum
Formula Science Notes
The formula combines 2% Sodium DNA, the cosmetic ingredient name used for PDRN, with 3% niacinamide, 0.5% bakuchiol, 0.5% squalane, 1% betaine, 0.2% sodium hyaluronate, and 0.2% dipotassium glycyrrhizate.
The peptide complex contains 0.1% Oligopeptide-1, 0.1% Acetyl Hexapeptide-8, and 0.1% Copper Tripeptide-1. Together, the formula is designed to support hydrated, smoother, fresher, more even-looking skin.
Supporting ingredient studies
- PDRN and skin-barrier-related laboratory research
- Randomized comparison of topical bakuchiol and retinol
- Clinical study of topical niacinamide on aging facial skin
These studies concern individual ingredients or other formulations, not the finished Cirela serum.
Our Product Testing
Study 1: 28-Day Human-Use Study
The finished serum was evaluated on 31 participants over 28 days using instrumental measurements, investigator assessments, and participant questionnaires.
Complete instrumental and investigator-assessed results after 28 days:
| Measurement | Change from baseline | Statistical result |
|---|---|---|
| Measured skin gloss | +33.04% | p<0.01 |
| Skin L* value | +3.95% | p<0.01 |
| Firmness-related F4 measurement | 7.42% improvement | p<0.01 |
| Measured surface oil | -44.70% | p<0.01 |
| Measured facial pore count | -4.00% | p<0.01 |
| Facial pore-area proportion | -6.05% | p<0.01 |
| Visible blemish red-area proportion | -48.46% | p<0.01 |
Additional blemish-related measurements recorded by the study
The study also included investigator-assessed blemish measurements. These results are included for transparency and are not presented as claims that the product treats acne or any medical condition.
| Study measurement | Change from baseline | Statistical result |
|---|---|---|
| Study's overall blemish score | -32.04% | p<0.01 |
| Investigator-counted comedones | -35.27% | p<0.01 |
| Investigator-counted papules | -53.59% | p<0.01 |
| Investigator-counted pustules | -76.19% | p<0.05 |
Participant-reported results after 28 days:
- More than 90% positively rated skin hydration, non-drying feel, smoothness, freshness, radiance, reduced dull-looking appearance, and more even-looking tone.
- More than 90% positively rated the formula as mild and non-irritating.
- More than 90% agreed that their skin appeared less prone to visible blemishes and that the number of visible blemishes appeared reduced.
- 100% positively rated the formula's soothing effect on the appearance of redness around blemish-prone areas.
- More than 80% positively rated reduced oiliness, improved appearance of enlarged pores, cleaner-looking pores, and reduced visible skin impurities.
- More than 70% positively rated smooth application.
The report stated that no adverse-reaction cases occurred during the 28-day study.
Study 2: Dermatological Skin-Tolerance Study
The finished serum underwent a 24-hour single-patch test. After patch removal, a dermatologist evaluated the test areas at 30 minutes, 24 hours, and 48 hours.
The report recorded zero observed reactions for erythema, dryness or scaling, and edema at each evaluation point under the controlled test conditions.
PDRN Pink Collagen Capsule Cream
Formula Science Notes
The cream combines 2% Sodium DNA with a multi-part hydration system containing 5% propylene glycol, 3% glycerin, 2% hydroxyethyl urea, 1% betaine, 0.2% hyaluronic acid, 0.2% sodium hyaluronate, and 0.2% panthenol.
The formula also contains 1% niacinamide, 0.1% soluble collagen, 0.1% collagen extract, 0.1% Acetyl Hexapeptide-8, 0.1% Copper Tripeptide-1, and 0.01% adenosine.
This humectant-heavy system is designed to attract and retain moisture so skin looks softer, smoother, and more cushioned. Topical collagen primarily supports surface conditioning and hydration. We do not claim that topical collagen replaces the collagen naturally present within the skin.
Supporting ingredient studies
- Clinical research on topical hyaluronic acid and skin hydration
- Clinical evaluation of Acetyl Hexapeptide-8
- Niacinamide research on ceramides and moisture-barrier function
These studies concern individual ingredients or other formulations, not the finished Cirela cream.
Our Product Testing
Study 1: Finished-Formula Laboratory Testing
Current finished-formula efficacy evidence for the cream comes from three separate in-vitro laboratory evaluations: moisture retention, elastase inhibition, and hyaluronidase inhibition.
Moisture-retention testing:
The laboratory monitored weight-based moisture retention at 25°C and 40% humidity. The finished formula recorded higher moisture-retention values than both reference controls at every measured timepoint.
| Timepoint | Cirela cream | Glycerin control | Polyethylene-glycol control |
|---|---|---|---|
| 2 hours | 128.14% | 93.77% | 93.22% |
| 4 hours | 94.00% | 86.98% | 87.61% |
| 6 hours | 91.69% | 82.11% | 79.79% |
| 8 hours | 87.60% | 75.80% | 73.86% |
| 24 hours | 75.99% | 64.80% | 63.23% |
These values are moisture-retention rates defined by the laboratory's in-vitro weight method. They are not percentages of increased moisture measured in human skin.
Elastase-inhibition testing:
Elastase inhibition is used as an in-vitro marker when evaluating the firming and wrinkle-smoothing potential of cosmetic formulas.
| Sample concentration | Elastase inhibition |
|---|---|
| 5% | 27.08% |
| 10% | 37.94% |
| 15% | 48.39% |
| 20% | 58.85% |
| 25% | 76.59% |
Hyaluronidase-inhibition testing:
Hyaluronidase inhibition is used as an in-vitro marker when evaluating the soothing potential of cosmetic formulas.
| Sample concentration | Hyaluronidase inhibition |
|---|---|
| 5% | 26.19% |
| 10% | 38.51% |
| 15% | 50.29% |
| 20% | 63.19% |
| 25% | 73.60% |
Elastase and hyaluronidase results were concentration-dependent laboratory findings. They are not measurements of wrinkle reduction, firmness improvement, or soothing effects in human users.
Study 2: Dermatological Skin-Tolerance Study
The finished cream underwent a 24-hour single-patch test. After patch removal, a dermatologist evaluated the test areas at 30 minutes, 24 hours, and 48 hours.
The report recorded zero observed reactions for erythema, dryness or scaling, and edema at each evaluation point under the controlled test conditions.
Glow Collagen Face Mask
Formula Science Notes
The mask contains a concentrated humectant system with 5% glycerin, 2% propylene glycol, and 2% betaine.
Its flexible hydrogel structure is formed with 1.608% sodium carrageenan, 1.2% Polyurethane-35, and 0.672% glucomannan. These materials help create a conforming mask that holds the water-based formula against the skin during wear.
The formula also contains 0.2% dipotassium glycyrrhizate, 0.1476% Galactomyces ferment filtrate, 0.1% allantoin, 0.1% niacinamide, 0.1% hydrolyzed collagen, 0.05% hydrolyzed sodium hyaluronate, and 0.05% sodium hyaluronate.
The mask's transition from milky to transparent is a physical change in the hydrogel during wear. It should not be presented as proof that a specific amount of product has entered the skin.
Supporting ingredient studies
- Human evaluation of a native collagen sheet mask
- Research on a transparent hyaluronic-acid hydrogel facial mask
- Clinical research on topical hyaluronic acid and skin hydration
These studies evaluated other mask materials, ingredients, or formulations, not the finished Cirela mask.
Our Product Testing
A finished-formula human-use efficacy study and dermatological patch study are not currently available for the Glow Collagen Face Mask. Its formula science should therefore be presented as ingredient and material rationale, not as finished-product clinical proof.
Results apply only to the specific finished formulas, batches, study populations, concentrations, methods, and controlled test conditions evaluated. Ingredient studies may involve different concentrations, delivery systems, or finished products. In-vitro laboratory results are not human-use outcomes. Dermatological patch testing evaluates observable skin reactions under controlled conditions and does not guarantee compatibility for every individual. Individual results may vary. Use only as directed. Patch test before first use and discontinue use if irritation occurs. Avoid direct contact with the eyes.